Sean Patrick Thomas Murphy, Mb.Bch,Bao
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Heart Failure | 15 | 2023 | 11670 | 1.370 |
Why?
|
Stroke Volume | 12 | 2023 | 5496 | 0.810 |
Why?
|
Neprilysin | 2 | 2023 | 478 | 0.780 |
Why?
|
Myocardial Infarction | 12 | 2024 | 11461 | 0.700 |
Why?
|
Tricuspid Valve Insufficiency | 1 | 2024 | 353 | 0.680 |
Why?
|
Atrial Natriuretic Factor | 1 | 2020 | 350 | 0.670 |
Why?
|
Pacemaker, Artificial | 1 | 2024 | 807 | 0.610 |
Why?
|
Drug Combinations | 6 | 2023 | 2048 | 0.580 |
Why?
|
Cardiotonic Agents | 1 | 2020 | 539 | 0.570 |
Why?
|
Mitral Valve Insufficiency | 2 | 2024 | 1400 | 0.560 |
Why?
|
Ventricular Remodeling | 2 | 2022 | 1267 | 0.560 |
Why?
|
Defibrillators, Implantable | 2 | 2024 | 1490 | 0.560 |
Why?
|
Heart Valve Diseases | 1 | 2024 | 1027 | 0.520 |
Why?
|
Myocarditis | 5 | 2021 | 788 | 0.500 |
Why?
|
Biphenyl Compounds | 5 | 2023 | 1007 | 0.480 |
Why?
|
International Classification of Diseases | 2 | 2019 | 909 | 0.480 |
Why?
|
Tetrazoles | 5 | 2023 | 909 | 0.470 |
Why?
|
Heart Valve Prosthesis Implantation | 1 | 2024 | 1553 | 0.430 |
Why?
|
Benchmarking | 1 | 2019 | 1045 | 0.430 |
Why?
|
Hypertension, Pulmonary | 1 | 2024 | 1578 | 0.420 |
Why?
|
Ventricular Dysfunction, Left | 2 | 2020 | 2118 | 0.410 |
Why?
|
Anterior Wall Myocardial Infarction | 2 | 2023 | 42 | 0.400 |
Why?
|
Primary Prevention | 1 | 2019 | 1186 | 0.380 |
Why?
|
Anti-Inflammatory Agents | 1 | 2020 | 1809 | 0.350 |
Why?
|
Angiotensin Receptor Antagonists | 5 | 2023 | 1039 | 0.340 |
Why?
|
Pulmonary Embolism | 1 | 2023 | 2567 | 0.340 |
Why?
|
Ventricular Function, Left | 7 | 2023 | 3879 | 0.310 |
Why?
|
Heart | 1 | 2021 | 4404 | 0.300 |
Why?
|
Aspirin | 1 | 2019 | 3133 | 0.280 |
Why?
|
Proteomics | 1 | 2021 | 3848 | 0.280 |
Why?
|
Heart Defects, Congenital | 1 | 2024 | 4671 | 0.280 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2019 | 2751 | 0.280 |
Why?
|
Acute Coronary Syndrome | 1 | 2019 | 2190 | 0.270 |
Why?
|
Registries | 4 | 2021 | 8224 | 0.260 |
Why?
|
Colchicine | 1 | 2024 | 259 | 0.210 |
Why?
|
Prognosis | 9 | 2023 | 29629 | 0.200 |
Why?
|
Coronary Vasospasm | 1 | 2022 | 81 | 0.190 |
Why?
|
Severity of Illness Index | 1 | 2019 | 15843 | 0.190 |
Why?
|
Inflammation | 2 | 2022 | 10773 | 0.190 |
Why?
|
Receptors, Angiotensin | 1 | 2021 | 141 | 0.180 |
Why?
|
Tricuspid Valve | 1 | 2024 | 410 | 0.180 |
Why?
|
Diuretics | 2 | 2022 | 610 | 0.180 |
Why?
|
Angiotensins | 1 | 2021 | 143 | 0.180 |
Why?
|
Plaque, Atherosclerotic | 2 | 2023 | 1533 | 0.180 |
Why?
|
Humans | 40 | 2024 | 761572 | 0.180 |
Why?
|
Amyloid Neuropathies, Familial | 1 | 2022 | 151 | 0.170 |
Why?
|
Fractional Flow Reserve, Myocardial | 1 | 2023 | 323 | 0.170 |
Why?
|
Echocardiography, Three-Dimensional | 1 | 2024 | 607 | 0.150 |
Why?
|
Competency-Based Education | 1 | 2020 | 222 | 0.150 |
Why?
|
Secondary Prevention | 1 | 2024 | 1475 | 0.150 |
Why?
|
Coronary Stenosis | 1 | 2023 | 794 | 0.140 |
Why?
|
Heart Injuries | 1 | 2019 | 206 | 0.140 |
Why?
|
Spironolactone | 1 | 2021 | 412 | 0.140 |
Why?
|
Health Services Misuse | 1 | 2019 | 244 | 0.140 |
Why?
|
Aged | 16 | 2024 | 169310 | 0.140 |
Why?
|
Heart Atria | 1 | 2022 | 1345 | 0.130 |
Why?
|
Treatment Outcome | 7 | 2024 | 64684 | 0.130 |
Why?
|
Patient Care Management | 1 | 2019 | 302 | 0.130 |
Why?
|
Heart Conduction System | 1 | 2021 | 1007 | 0.130 |
Why?
|
Mitral Valve | 1 | 2024 | 1465 | 0.120 |
Why?
|
Cardiovascular System | 1 | 2022 | 834 | 0.120 |
Why?
|
Health Status Indicators | 1 | 2020 | 970 | 0.120 |
Why?
|
Adrenal Cortex Hormones | 2 | 2020 | 1881 | 0.120 |
Why?
|
Cardiovascular Diseases | 2 | 2020 | 15501 | 0.110 |
Why?
|
Heart Valve Prosthesis | 1 | 2022 | 1462 | 0.110 |
Why?
|
Physical Examination | 1 | 2020 | 1255 | 0.110 |
Why?
|
Clinical Trials as Topic | 2 | 2020 | 8002 | 0.110 |
Why?
|
Action Potentials | 1 | 2021 | 1834 | 0.110 |
Why?
|
Coronary Artery Disease | 2 | 2023 | 6403 | 0.110 |
Why?
|
Practice Guidelines as Topic | 2 | 2020 | 7391 | 0.100 |
Why?
|
Middle Aged | 15 | 2024 | 220920 | 0.100 |
Why?
|
Patient Readmission | 3 | 2023 | 3271 | 0.100 |
Why?
|
Aged, 80 and over | 7 | 2021 | 58986 | 0.100 |
Why?
|
Diagnostic Errors | 1 | 2019 | 1265 | 0.100 |
Why?
|
Influenza Vaccines | 1 | 2019 | 768 | 0.090 |
Why?
|
Risk Factors | 7 | 2024 | 74213 | 0.090 |
Why?
|
Echocardiography | 2 | 2022 | 4989 | 0.090 |
Why?
|
Cardiomyopathies | 1 | 2022 | 1964 | 0.090 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2020 | 10766 | 0.090 |
Why?
|
Aortic Valve Stenosis | 1 | 2022 | 2001 | 0.090 |
Why?
|
Patient Discharge | 2 | 2020 | 3443 | 0.090 |
Why?
|
Risk Assessment | 6 | 2021 | 23996 | 0.090 |
Why?
|
Male | 17 | 2024 | 360842 | 0.090 |
Why?
|
Health Status | 1 | 2022 | 4077 | 0.080 |
Why?
|
Heart Rate | 1 | 2021 | 4195 | 0.080 |
Why?
|
Female | 16 | 2024 | 392686 | 0.080 |
Why?
|
Influenza, Human | 1 | 2019 | 1521 | 0.070 |
Why?
|
Electrocardiography | 1 | 2021 | 6377 | 0.070 |
Why?
|
Echocardiography, Doppler | 2 | 2023 | 897 | 0.070 |
Why?
|
Neoplasms | 3 | 2022 | 22173 | 0.070 |
Why?
|
Hemorrhage | 1 | 2019 | 3424 | 0.070 |
Why?
|
Prevalence | 2 | 2020 | 15732 | 0.060 |
Why?
|
Sex Factors | 1 | 2019 | 10553 | 0.060 |
Why?
|
Thrombosis | 1 | 2019 | 2942 | 0.060 |
Why?
|
Atherosclerosis | 1 | 2020 | 3408 | 0.060 |
Why?
|
Clinical Competence | 1 | 2020 | 4793 | 0.060 |
Why?
|
Natriuretic Peptide, Brain | 2 | 2022 | 1723 | 0.050 |
Why?
|
Anticoagulants | 1 | 2019 | 4812 | 0.050 |
Why?
|
Prospective Studies | 3 | 2023 | 54426 | 0.050 |
Why?
|
Technetium Tc 99m Pyrophosphate | 1 | 2022 | 45 | 0.050 |
Why?
|
Diphosphates | 1 | 2022 | 84 | 0.050 |
Why?
|
Technetium | 1 | 2022 | 317 | 0.050 |
Why?
|
Magnetic Resonance Imaging, Cine | 2 | 2020 | 1050 | 0.050 |
Why?
|
Predictive Value of Tests | 3 | 2023 | 15266 | 0.050 |
Why?
|
Prealbumin | 1 | 2022 | 222 | 0.050 |
Why?
|
Nitrates | 1 | 2022 | 263 | 0.050 |
Why?
|
Ireland | 1 | 2020 | 170 | 0.040 |
Why?
|
Enalapril | 1 | 2022 | 312 | 0.040 |
Why?
|
Constriction, Pathologic | 1 | 2023 | 1096 | 0.040 |
Why?
|
Internship and Residency | 1 | 2020 | 5882 | 0.040 |
Why?
|
Retrospective Studies | 7 | 2022 | 80646 | 0.040 |
Why?
|
Calcium Channel Blockers | 1 | 2022 | 694 | 0.040 |
Why?
|
Ischemic Attack, Transient | 1 | 2024 | 882 | 0.040 |
Why?
|
Radionuclide Imaging | 1 | 2022 | 1972 | 0.040 |
Why?
|
Hospitalization | 3 | 2024 | 10721 | 0.040 |
Why?
|
Myocardial Contraction | 1 | 2023 | 1515 | 0.040 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2022 | 12148 | 0.040 |
Why?
|
Troponin I | 1 | 2022 | 651 | 0.040 |
Why?
|
Vasodilator Agents | 1 | 2022 | 973 | 0.040 |
Why?
|
Angiography | 1 | 2022 | 1595 | 0.040 |
Why?
|
Fluorouracil | 1 | 2022 | 1642 | 0.030 |
Why?
|
Troponin T | 1 | 2022 | 780 | 0.030 |
Why?
|
Antineoplastic Agents | 1 | 2020 | 13642 | 0.030 |
Why?
|
Boston | 2 | 2020 | 9326 | 0.030 |
Why?
|
Myocardial Revascularization | 1 | 2020 | 790 | 0.030 |
Why?
|
Survival Analysis | 2 | 2019 | 10090 | 0.030 |
Why?
|
Massachusetts | 2 | 2019 | 8830 | 0.030 |
Why?
|
Gadolinium | 1 | 2020 | 960 | 0.030 |
Why?
|
Angina, Unstable | 1 | 2019 | 888 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2023 | 2330 | 0.030 |
Why?
|
Time Factors | 3 | 2021 | 39970 | 0.030 |
Why?
|
Chest Pain | 1 | 2020 | 1091 | 0.030 |
Why?
|
Cholesterol | 1 | 2022 | 2904 | 0.030 |
Why?
|
Aortic Valve | 1 | 2022 | 1955 | 0.030 |
Why?
|
Drug Administration Schedule | 1 | 2020 | 4853 | 0.020 |
Why?
|
Coronary Angiography | 1 | 2023 | 4471 | 0.020 |
Why?
|
Recurrence | 1 | 2024 | 8466 | 0.020 |
Why?
|
C-Reactive Protein | 1 | 2022 | 3826 | 0.020 |
Why?
|
Academic Medical Centers | 1 | 2020 | 2759 | 0.020 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2020 | 3769 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 2 | 2023 | 20571 | 0.020 |
Why?
|
Cause of Death | 1 | 2020 | 3683 | 0.020 |
Why?
|
Acute Disease | 1 | 2019 | 7237 | 0.020 |
Why?
|
Proportional Hazards Models | 1 | 2022 | 12463 | 0.020 |
Why?
|
Animals | 1 | 2020 | 168467 | 0.020 |
Why?
|
Mortality | 1 | 2019 | 2901 | 0.020 |
Why?
|
Contrast Media | 1 | 2020 | 5311 | 0.020 |
Why?
|
Students, Medical | 1 | 2020 | 1936 | 0.020 |
Why?
|
Vaccination | 1 | 2019 | 3384 | 0.020 |
Why?
|
Physician-Patient Relations | 1 | 2020 | 3249 | 0.020 |
Why?
|
Curriculum | 1 | 2020 | 3743 | 0.020 |
Why?
|
Cohort Studies | 2 | 2019 | 41493 | 0.020 |
Why?
|
Hospitals | 1 | 2019 | 3882 | 0.020 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2020 | 3245 | 0.020 |
Why?
|
Hospital Mortality | 1 | 2019 | 5293 | 0.020 |
Why?
|
Comorbidity | 1 | 2019 | 10508 | 0.010 |
Why?
|
Disease Progression | 1 | 2020 | 13510 | 0.010 |
Why?
|
Stroke | 1 | 2024 | 9758 | 0.010 |
Why?
|
United States | 2 | 2020 | 72335 | 0.010 |
Why?
|
Melanoma | 1 | 2020 | 5709 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2019 | 22176 | 0.010 |
Why?
|
Lung Neoplasms | 1 | 2020 | 13382 | 0.010 |
Why?
|